ClinicalTrials.gg
TerminatedNCT06125522Updated Oct 27, 2026

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)

A Phase 1/2 interventional study of vepdegestrant and Samuraciclib in Breast Cancer, sponsored by Pfizer. Terminated at 23 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Pfizer · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Enrollment was permanently closed for strategic business reasons after 11 participants enrolled in Ph1b. The decision was not related to safety, efficacy, benefit-risk, or participant welfare. The planned Ph2 and DDI components were not initiated.
Updated Oct 27, 2026Now TerminatedNow Completed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing vepdegestrant in Breast Neoplasms — 1 open to participants now, 6 under way, 2 of them phase 3. vepdegestrant · Breast Neoplasms.

Enrollment
10th of 12
11 · median 48
Started
2024
with 1 other
Phase 1/2
5 of 12
none open now
Registered
11th of 12
by date
Lead sponsor
8 of 12
Pfizer

Among the 12 studies testing vepdegestrant in Breast Neoplasms, this one is the 10th largest by enrollment, is one of 2 that started in 2024, is one of 5 in phase 1/2, and was the 11th registered.

Breast Neoplasms

14,840 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

1 of the 12 studies testing vepdegestrant in Breast Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vepdegestrant

vepdegestrant: first FDA approval 2026 (VEPPANU). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,398 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 590 (25%) stop at 75 or younger; 103 take children under 18; 213 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing vepdegestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to learn about the safety and effects of the study medicine called vepdegestrant. The safety and effects of vepdegestrant will be see when given with other medicines. Vepdegestrant is studied to see if it can be a possible treatment for advanced metastatic breast cancer. This type of cancer would have spread from where it started (breast) to other parts of the body and would be tough to treat.

The study is seeking for participants who have breast cancer that:

  • is hard to treat (advanced) and may have spread to other organs (metastatic). is sensitive to hormonal therapy (it is called estrogen receptor positive).
  • is no longer responding to treatments taken before starting this study.

This study is divided into separate sub-studies.

For Sub-Study C:

All the participants will receive vepdegestrant and a medicine called samuraciclib.

Vepdegestrant and samuraciclib will be taken once in a day by mouth. The medicines will be taken at home. The experience of people receiving the study medicines will be studied. This will help see if the study medicine is safe and effective.

Participant will continue to take vepdegestrant and samuraciclib until:

  • their cancer is no longer responding, or
  • side effects become too severe.

They will have visits at the study clinic about every 4 weeks.

Read the detailed description

C4891024 is a prospective, open-label, multicenter, Phase 1b/2 sub-study to evaluate the safety, antitumor activity, and PK of ARV-471 with samuraciclib in the treatment of participants with A/MBC. The sub-study is part of Umbrella platform, TACTIVE-U, comprising multiple sub-studies that independently evaluate ARV-471 in participants with Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Advanced or Metastatic Breast Cancer. ARV-471 will act as the backbone therapy given in combination with other anticancer agents thought to have clinical relevance in ER+ breast cancer.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • TACTIVE-U
  • Umbrella study
  • PROTAC
  • metastatic breast cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological or cytological diagnosis of breast cancer. At time of enrollment this must not be amendable to surgical resection with curative intent (≥1% ER+ stained cells as per local practice on the most recent tumor - tumor by IHC or in-situ hybridization per ASCO/CAP).
  • prior anticancer therapies: up to 2 for advanced/ disease; 1 line of any CDK4/6 inhibitor-based regimen is required (in any setting eg adjuvant, metastatic)
  • at least 1 as defined by v1.1.
  • PS ≤1.

Exclusion criteria

Exclusion Criteria:

  • visceral crisis at risk of life-threatening complications in the short term
  • known history of drug-induced pneumonitis or other significant symptomatic deterioration of lung functions.
  • newly diagnosed , or symptomatic CNS metastases, carcinomatous meningitis, or . Participants with a history of CNS metastases or cord compression are eligible if they have been definitively treated, clinically stable and discontinued anti-seizure medications and for at least 28 days prior to enrollment in the of study.
  • history of any other tumor within the past 3 years, except for the following: (1) adequately treated basal or squamous cell carcinoma of the skin; (2) curatively treated in situ carcinoma of the cervix.
  • inflammatory breast cancer
  • impaired cardiovascular function or cardiovascular diseases
  • concurrent administration of medications, food, or herb supplements that are strong inhibitors/inducers of , strong CYP2D6 inhibitors and drugs known to predispose to Torsade de Pointes or prolongation.
  • renal impairment, not adequate liver function and/or bone marrow function
  • known active infection
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    ARV-471 in combination with Samuraciclib

    ARV-471 administered orally QD continuously and Samuraciclib administered orally QD continuously on 28-day cycles

    Drug: vepdegestrant · Drug: Samuraciclib

Interventions

  • Daily oral dosages of ARV-471 continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days

    Also known as: ARV-471 / PF-07850327

  • Daily oral dosages of Samuraciclib continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days

06

What researchers measure

Primary outcomes

  1. Phase 1b: Number of Participants With Dose Limiting Toxicities

    Dose Limiting Toxicities rate for ARV-471 in combination with Samuraciclib, estimated based on data from DLT-evaluable participants during the DLT observation period (Cycle 1).

    Time frame: 28 days

  2. Drug Drug Interaction: To evaluate the effect of samuraciclib on PK of ARV 471.

    Steady-state Area under the plasma concentration versus time curve (AUCtau) of ARV-471 with and without coadministration of samuraciclib

    Time frame: From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days)

  3. Drug Drug Interaction: To evaluate the effect of samuraciclib on PK of ARV 471.

    Steady-state Peak Plasma concentration ( Cmax) of ARV-471 with and without coadministration of samuraciclib

    Time frame: From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days)

  4. Phase 2: Percentage of Participants With Objective Response by investigator assessment

    Objective response (OR) refers to confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1. as determined by investigator assessment.

    Time frame: Up to approximately 1 year

  5. Drug Drug Interaction: • To evaluate the effect of ARV 471 on PK of samuraciclib.

    Single dose AUC0-72 of samuraciclib with and without coadministration of ARV 471.

    Time frame: From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days))

  6. Drug Drug Interaction: • To evaluate the effect of ARV 471 on PK of samuraciclib.

    Single dose Cmax of samuraciclib with and without coadministration of ARV 471.

    Time frame: From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days))

Secondary outcomes

  1. Phase 1b, Drug drug interaction and Phase 2: Evaluation of Safety and Tolerability of ARV-471 in combination with Samuraciclib

    AEs as characterized by type, frequency, intensity as graded by NCI CTCAE version 5.0, timing, seriousness, and relationship to ARV-471 in combination with samuraciclib. Laboratory test abnormalities as characterized by type, frequency, intensity (as graded by NCI CTCAE version 5.0), and timing. Changes from baseline for the ECG parameters heart rate, QTcF, PR interval, and QRS complex will be summarized by treatment and time. The frequency of uncorrected QT values above 500 ms will be tabulated.

    Time frame: First study drug dose through a minimum of 28 Days After Last study drug administration

  2. Phase 1b: To evaluate antitumor activity of ARV-471 in combination with samuraciclib

    Objective response (OR) refers to confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1. as determined by investigator assessment.

    Time frame: Up to approximately 1 year

  3. Phase 1b and Phase 2: Duration of Response by investigator assessment.

    Duration of Response (DoR) is defined for participants with confirmed OR (CR or PR) as the time from the first documentation of OR to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first.

    Time frame: Up to approximately 1 year

  4. Phase 1b and Phase2: Percentage of participants with Clinical Benefit Response by investigator assessment.

    Clinical Benefit Response (CBR) is defined as the proportion of participants with Best Overall Response of confirmed CR or PR at any time, or Stable Disease (SD) ≥24 weeks

    Time frame: Up to approximately 1 year

  5. Phase 1b and Phase 2: Progression Free Survival by investigator assessment.

    Progression Free Survival (PFS) is defined as the time from the date of first dose of study interventions to the date of first documentation of PD or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 1 year

  6. Phase 1b and Phase 2: Plasma concentrations of ARV-471 and samuraciclib.

    To evaluate the plasma exposure of ARV-471 and samuraciclib when ARV-471 and samuraciclib are given in combination.

    Time frame: At predefined intervals throughout the treatment period, up to cycle 7 (each cycle is 28 days)

  7. Phase 1b: Evaluation of effect of samuraciclib on PK of ARV-471

    AUCtau of ARV-471 with and without co-administration of samuraciclib

    Time frame: At predefined intervals throughout the treatment period, up to cycle 7 (each cycle is 28 days)

  8. Phase 1b: Evaluation of effect of samuraciclib on PK of ARV-471

    Cmax of ARV-471 with and without co-administration of samuraciclib

    Time frame: At predefined intervals throughout the treatment period, up to cycle 7 (each cycle is 28 days)

  9. Phase 2:ctDNA plasma quantitative changes from pre-treatment

    To assess changes from baseline levels in plasma ctDNA with treatment and to evaluate potential predictability of their associations with clinical outcomes.

    Time frame: At predefined intervals throughout the treatment period, up to cycle 3 (each cycle is 28 days) and end of treatment

  10. Phase 2: To evaluate the correlation between TP53 mutation status and antitumor activity

    Participants classified on basis of pathological TP53 mutation detected or not detected.

    Time frame: Screening

  11. Phase 2: Overall Survival

    Overall Survival (OS) is defined as the time from the date of first dose of study interventions to the date of death due to any cause

    Time frame: Through study completion, up to approximately 3 year

07

Study locations

23 sites
  • Highlands Oncology Group
    Fayetteville, Arkansas 72703, United States
  • Highlands Oncology Group
    Rogers, Arkansas 72758, United States
  • Highlands Oncology Group
    Springdale, Arkansas 72762, United States
  • Clinical and Translational Research Unit (CTRU)
    Palo Alto, California 94304, United States
  • Stanford Cancer Institute - Clinical Trials Office
    Palo Alto, California 94304, United States
  • Stanford Women's Cancer Center
    Palo Alto, California 94304, United States
  • UCHealth Poudre Valley Hospital
    Fort Collins, Colorado 80524, United States
  • UCHealth Harmony
    Fort Collins, Colorado 80528, United States
  • UCHealth Greeley Hospital
    Greeley, Colorado 80634, United States
  • UCHealth - Medical Center of the Rockies
    Loveland, Colorado 80538, United States
  • Memorial Hospital East
    Shiloh, Illinois 62269, United States
  • Siteman Cancer Center - Shiloh
    Shiloh, Illinois 62269, United States
  • Siteman Cancer Center - St Peters
    City of Saint Peters, Missouri 63376, United States
  • Siteman Cancer Center - West County
    Creve Coeur, Missouri 63141, United States
  • Siteman Cancer Center - North County
    Florissant, Missouri 63031, United States
  • Barnes-Jewish Hospital
    St Louis, Missouri 63110, United States
  • Washington University School of Medicine - Siteman Cancer Center
    St Louis, Missouri 63110, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • Siteman Cancer Center - South County
    St Louis, Missouri 63129, United States
  • Institut Jules Bordet
    Anderlecht, Bruxelles-capitale, Région de 1070, Belgium
  • Centre Georges François Leclerc
    Dijon, Côte-d'or 21079, France
  • Fondazione IRCCS San Gerardo dei Tintori
    Monza, Lombardy 20900, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore
    Roma, 00168, Italy
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jan 2024 to primary completion in Sep 2026, 32 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Dec 2026 → Sep 2026 and completion Dec 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2023
First posted
Nov 9, 2023
StartActual
Jan 10, 2024
Primary completionActual
Sep 10, 2026was Dec 2026
CompletionActual
Sep 10, 2026was Dec 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed→Terminated Enrollment was permanently closed for strategic business reasons after 11 participants enrolled in Ph1b. The decision was not related to safety, efficacy, benefit-risk, or participant welfare. The planned Ph2 and DDI components were not initiated.
changed Oct 2, 2026 · changed Oct 27, 2026
Sites
2 sites added
Show 2 added (2 United States)
  • Stanford Cancer Institute - Clinical Trials Office · Palo Alto, United States
  • Washington University School of Medicine · St Louis, United States
Oct 2, 2026
Primary completion
Dec 31, 2026→Sep 10, 2026 (actual)
Oct 2, 2026
Study completion
Dec 31, 2026→Sep 10, 2026 (actual)
Oct 2, 2026
Sponsor
Collaborators added: Rigel Pharmaceuticals,Inc.
Oct 2, 2026
Show all 2 updates
  1. Oct 27, 2026
    Completed→Terminated
    Why stopped Enrollment was permanently closed for strategic business reasons after 11 participants enrolled in Ph1b. The decision was not related to safety, efficacy, benefit-risk, or participant welfare. The planned Ph2 and DDI components were not initiated.
    + 1 other change: verification date
  2. Oct 2, 2026
    Active, not recruiting→Completed
    2 sites added
    Show 2 added (2 United States)
    • Stanford Cancer Institute - Clinical Trials Office · Palo Alto, United States
    • Washington University School of Medicine · St Louis, United States
    Primary completion Dec 31, 2026→Sep 10, 2026 (now actual)
    Study completion Dec 31, 2026→Sep 10, 2026 (now actual)
    Sponsor Collaborators added: Rigel Pharmaceuticals,Inc.
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06125522
Lead sponsor
Pfizer
Collaborators
Arvinas Estrogen Receptor, Inc., Carrick Therapeutics Limited, Rigel Pharmaceuticals,Inc.
Responsible party
Sponsor
First posted
Nov 9, 2023
Start date
Jan 10, 2024
Primary completion
Sep 10, 2026
Completion
Sep 10, 2026
Last update
Oct 27, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vepdegestrant · Samuraciclib

Start the discussion